



**GENIZON
BioSciences**

Genizon BioSciences Inc.
880 McCaffrey St.
St. Laurent, Quebec H4T 2C7
Tel : (514) 270-3991
Fax : (514) 270-5291
1-888-244-0388
www.genizon.com

Press Release

11 • 06 • 2007

GENIZON BIOSCIENCES COLLABORATING WITH NDEI TO ENHANCE GENE DISCOVERY FINDINGS IN SCHIZOPHRENIA

November 6, 2007 – Montreal, QC – Genizon BioSciences Inc. and Neuropsychiatrie, Découverte & Innovation Inc. (NDEI) today announced an agreement under which the groups will collaborate to enhance and potentially add to discoveries made by Genizon early this year in a genome-wide association study of schizophrenia. Genizon's study identified multiple genes associated with the disease using DNA samples from patients from the Quebec Founder Population.

Schizophrenia is a chronic, severe and disabling disease of the central nervous system affecting between 0.5% and 1% of the adult population worldwide. The causes involve both genetic and environmental factors. Treatment generally involves the use of antipsychotic medication which is effective in treating some disease symptoms, but can also produce significant side effects.

NDEI, under the leadership of Dr. Michel Maziade, president of NeuroCité, scientific director of the Centre de recherche Université Laval Robert-Giffard (CRULRG) and professor of Psychiatry at the University of Laval, will be supplying a second set of samples collected from the Quebec founder population. Genotyping of these samples and statistical analyses of the data will be conducted at Genizon's St. Laurent, Quebec research center.

"We are delighted to be working with Dr. Maziade and his group," said Dr. John Hooper, President and CEO of Genizon. "They have advanced expertise in schizophrenia research, and this collaboration has significant potential to enhance our discoveries in this disease."

"Schizophrenia is a truly devastating disease for both those afflicted and their families," commented Dr. Maziade. "We expect the results of these studies to lead to a new generation of safer and more effective treatments tailored to individual schizophrenia patients. We are thrilled to be collaborating with Genizon to achieve this goal."

Genizon has conducted eight genome-wide association studies to date, covering a range of therapeutic areas. All studies have used samples from the Quebec Founder Population which, because of its high level of genetic homogeneity, is considered among the best populations worldwide for disease gene discovery.

Genizon and NDEI are dedicated to accelerating the development of diagnostic and therapeutic solutions to schizophrenia.

SOVAR, the Société de valorisation des applications de la recherche of Laval University and affiliated hospitals, negotiated on behalf of NDEI for this agreement.

About Genizon

Genizon BioSciences Inc., founded in 1999, is the only source for GeneMaps-comprehensive maps of genes, genetic markers, biochemical pathways and drug targets that are unequivocally involved in causing human disease-accelerating the development of safer, more effective medicines. GeneMaps also lead to the development of predictive diagnostics that facilitate personalized medicine. Genizon's proprietary, automated gene discovery platform using genome-wide association studies involving thousands of members of the Quebec Founder Population provides unprecedented understanding of the genetic origins and mechanisms of common diseases, resulting in the best possible drug targets and genetic markers. The company's GeneMaps provide pharmaceutical partners with intellectual property that creates opportunities for leadership in many therapeutic areas by bringing to market better treatments that address the root causes of diseases. Genizon is conducting gene discovery programs in more than 25 common diseases. Genizon also provides high-throughput, high-quality SNP genotyping, genetic analysis, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

About NDEI

NDEI, a spin-off company of the Centre de recherche Université Laval Robert-Giffard (CRULRG) is in the foreground of psychiatric genomic research. Our mission is: to perform genetic and medical research to identify disease genes, and drug and diagnostic targets for neuropsychiatric disorders, particularly schizophrenia and bipolar disorders; to use modern informatics technology to discover facts about mental health and neuropsychiatric disease through the use of extensive clinical and DNA banks and longitudinal access, established over the past 12 years, with the Eastern Quebec population and its psychiatric clinical network; to use this knowledge to develop products and services for the international mental healthcare industry. NDEI was founded in 2002 and is based in Quebec City, Canada.

SOVAR is a limited partnership whose mission is to promote the discoveries and innovations developed by researchers at Université Laval, the CHUQ and the CHRQ. SOVAR's experts work in synergy with the researchers to promote their projects. The products, processes, services or technologies developed are ultimately transferred to existing companies or to new companies created to bring them to market.

Contacts:

Caroline Fortier
Vice President, Corporate Development
Genizon BioSciences Inc.
514.708.4417
caroline.fortier@genizon.com

Lauren Arnold/Wendy Mejia
Schwartz Communications
781.684.0770
genizon@schwartz-pr.com

Dr. Michel Maziade
Director
NDEI
418.663.5744
ndei@ndei.ca